
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix is expected to see strong growth in the coming years due to the commercialization of its flagship product, DefenCath, and the diversification of its portfolio through the acquisition of Momenta. The company has already achieved significant operating synergies and has a strong cash position with near-zero net debt. The potential launch of Rezzayo and DefenCath in the Total Parenteral Nutrition market could provide additional revenue streams and significantly increase the company's market potential. Despite the recent stock reaction, the company's potential for sustained growth and successful clinical execution make it a promising investment opportunity.
Bears say
Cormedix is a biopharmaceutical company with a negative outlook as the launch of its new drug Rezzayo for prophylaxis in high-risk immunocompromised patients is not expected until 2026 and there are uncertainties around its peak penetration. Additionally, the company may require additional funding to achieve sustainable profitability and there is no guarantee of obtaining favorable financing terms or attracting new partners. The existing treatment franchise is conservatively valued due to formulary dynamics, shorter treatment duration and measured hospital adoption, further limiting potential revenue growth.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares